To further elucidate pyrotinib’s mechanism of activity and identified the potential targets of pyrotinib, we analyzed phosphorylation statuses of EGFR, HER2 and HER4 – the established therapeutic targets of this pan-HER inhibitor across seven GC cell lines following pyrotinib treatment. This evidence concerns the gene ERBB4 and gastric cancer.